3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Hodgkin Disease
3
Breast Neoplasms
3
Lymphoma, Non-Hodgkin
2
Leukemia
2
Triple Negative Breast Neoplasms
1
Teratoma
1
Rhabdomyosarcoma
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Pain
1
Lymphoma, T-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, AIDS-Related
1
Lymphoma
1
Inflammatory Breast Neoplasms
1
Infiltrating Bladder Urothelial Carcinoma
1
Glioma
1
Choriocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Embryonal
1
Burkitt Lymphoma
1
Adenocarcinoma, Bronchiolo-Alveolar
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
22
Nivolumab
14
enfortumab vedotin
13
Gemcitabine
11
Specimen Handling
9
Magnetic Resonance Spectroscopy
9
Cisplatin
8
Carboplatin
8
sacituzumab govitecan
6
Docetaxel
6
avelumab
5
atezolizumab
5
Ipilimumab
5
durvalumab
4
Paclitaxel
4
cabozantinib
3
Taxes
3
Mitomycin
3
CTLA-4 Antigen
3
tislelizumab
2
relatlimab
2
erdafitinib
2
disitamab vedotin
2
Radiosurgery
2
Platinum
2
Oxaliplatin
2
Immunoglobulin G
2
Fluorouracil
2
Disulfides
2
ALT-803
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
pegfilgrastim
×
90 days
×
Clear all
No trials found.